As of Feb 12
| -0.27 / -4.62%|
The 5 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 9.00. The median estimate represents a +79.53% increase from the last price of 5.57.
The current consensus among 6 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.